Vericel Corp (VCEL) Hits New High on Drug Data

Vericel Corp's (NASDAQ:VCEL) heart failure treatment met its main goals in a Phase 2 study

Mar 11, 2016 at 1:17 PM
facebook twitter linkedin


Cellular therapy stock Vericel Corp (NASDAQ:VCEL) exploded for an 86.3% gain on Thursday, with trading volume reaching an annual high, after the company announced that its heart failure treatment candidate met its main goals in a Phase 2 study. VCEL plans to give more information about the trial on Monday, April 4. The shares have added another 5.8% today to trade at $4.18, and earlier hit an annual high of $5.18. In the meantime, the stock has seen a rare dose of option trading. 

There's usually next to no activity in VCEL's option pits, but that's changed over the past two days. Yesterday, over 1,000 calls crossed, with much of the activity occurring at the March 5 call -- where it's likely long positions were added. Another 1,000 calls have been traded in today's session, and it looks like traders may have liquidated their VCEL March 5 calls, taking profits on the earlier move above $5. 

Despite the positive development, many speculators may be hesitant to place bullish bets on Vericel Corp (NASDAQ:VCEL), given its technical track record. The 10-year chart below should tell the whole story:

160311VCEL

Sign up now for Schaeffer's Market Recap to get all the day's big stock movers, must-know technical levels, and top economic stories straight to your inbox.

 

If you are not making money with options, you aren’t buying options like this…

There is no options strategy that more perfectly approaches trading the fastest moving and most volatile stocks available in the marketplace than this one. In fact, there is no strategy that better utilizes put options for optimal returns and a real trading edge over other traders in the exact same market. New options traders fail out at an incredible rate without proper trade research, execution timing, and option picking. Capitalize on Schaeffer’s 100+ years of options trading excellence with the most coveted product launch in company history. Don't waste another second... join us right now before the next round of trades are released!

Schaeffer's Investment Research Master Portfolio Trial
 


 


 
Special Offers from Schaeffer's Trading Partners